Vivalytic SARS-CoV-2, Flu A/B, RSV Test
Patients infected with SARS-CoV‑2, Influenza A (Flu A), Influenza B (Flu B) and/or Respiratory Syncytial Virus (RSV) have overlapping symptoms, but the approaches to patient management of infections caused by the viruses are different. The Vivalytic SARS-CoV‑2 DT, Flu A/B, RSV test detects and differentiates between these viral nucleic acids, aiding diagnosis and enabling pathogen-specific management of patients.
The SARS coronavirus 2 (SARS-CoV‑2) is a respiratory pathogen which is responsible for the novel disease COVID-19. With over 10 million cases and 500,000 deaths reported as of end of June 2020, COVID-19 is challenging health care systems and society all over the world.
Influenza, also called flu, is a contagious respiratory disease caused by influenza viruses. An influenza infection causes mild to severe illness and can be lethal. In Europe, seasonal influenza causes between 4 and 50 million symptomatic cases each year and the death toll associated with influenza is estimated to be between 15,000 and 70,000 every influenza season, in terms of excess deaths.
The Respiratory syncytial virus (RSV) is a pathogen for acute diseases of the upper and lower respiratory tract. Especially infants and young children are at risk of developing a severe RSV infection resulting in hospitalization.
The high burden caused each year by SARS-CoV‑2, influenza and RSV shows how important it is to identify the different viruses quickly in order to provide the patient with targeted treatment. The combination test additionally reduces costs.
Respiratory infections
- Influenza A
- Influenza B
- Human respiratory syncytial virus (RSV)
- SARS-CoV‑2
Product Specifications
|
Sample Type |
Nasopharyngeal and/or oropharyngeal swab |
|---|---|
|
Sample Input Volume |
300µl |
|
Reagent Storage Conditions |
15 – 25 °C |
|
|
|
Ordering Information
|
Product |
Pack size |
Order number |
|---|---|---|
|
Vivalytic SARS-CoV‑2, Flu A/B, RSV |
15 cartridges |
|